|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.60 HKD | -2.25% |
|
+3.87% | +5.26% |
| Feb. 03 | Simcere Pharma Secures $40 Million Milestone Payment from AbbVie Collaboration | MT |
| Jan. 27 | Simcere Pharmaceutical Sells License to IBD Drug | MT |
| Capitalization | 4.17B 32.56B 3.51B 3.21B 3.06B 5.68B 378B 5.89B 37.25B 14.81B 182B 15.62B 15.3B 639B | P/E ratio 2025 * |
23x | P/E ratio 2026 * | 19x |
|---|---|---|---|---|---|
| Enterprise value | 4.07B 31.83B 3.44B 3.13B 2.99B 5.55B 370B 5.76B 36.42B 14.48B 178B 15.28B 14.96B 625B | EV / Sales 2025 * |
3.72x | EV / Sales 2026 * | 3.13x |
| Free-Float |
29.6% | Yield 2025 * |
2.22% | Yield 2026 * | 2.71% |
| 1 day | -2.25% | ||
| 1 week | +3.87% | ||
| Current month | +7.78% | ||
| 1 month | +8.43% | ||
| 3 months | -9.03% | ||
| 6 months | +1.20% | ||
| Current year | +5.26% |
| 1 week | 12.11 |  | 12.92 |
| 1 month | 11.08 | | 12.92 |
| Current year | 10.6 | | 12.92 |
| 1 year | 6.9 | | 15.08 |
| 3 years | 4.94 | | 15.08 |
| 5 years | 4.94 | | 15.08 |
| 10 years | 4.94 | | 15.08 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jin Sheng Ren
CEO | Chief Executive Officer | 63 | 2014-01-16 |
Yu Shan Wan
DFI | Director of Finance/CFO | 55 | 2019-11-18 |
Gaobo Zhou
CIO | Chief Investment Officer | 47 | 2022-01-16 |
| Director | Title | Age | Since |
|---|---|---|---|
Jin Sheng Ren
CHM | Chairman | 63 | 2012-10-07 |
Yu Shan Wan
BRD | Director/Board Member | 55 | 2019-11-18 |
Ren Hong Tang
BRD | Director/Board Member | 46 | 2019-10-31 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.25% | +3.87% | +80.00% | +25.00% | 4.26B | |
| +0.18% | +0.32% | 0.00% | +70.84% | 44.97B | |
| +1.18% | +14.62% | +46.21% | +155.12% | 36.57B | |
| +1.87% | +1.98% | -7.06% | +31.59% | 11.88B | |
| +0.64% | +2.51% | +0.95% | +94.00% | 10.05B | |
| +2.69% | +7.00% | +205.37% | +974.30% | 8.62B | |
| -0.84% | +1.73% | +43.29% | +121.70% | 8.5B | |
| -1.21% | +7.31% | +74.68% | +37.58% | 8.19B | |
| +0.34% | +2.44% | +67.38% | -10.84% | 7.8B | |
| -0.68% | -0.43% | +8.50% | +47.46% | 6.68B | |
| Average | +0.18% | +2.88% | +51.93% | +154.67% | 14.75B | |
| Weighted average by Cap. | +0.50% | +4.02% | +35.86% | +137.35% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.1B 8.56B 924M 843M 803M 1.49B 99.43B 1.55B 9.79B 3.89B 47.87B 4.11B 4.02B 168B | 1.32B 10.35B 1.12B 1.02B 972M 1.8B 120B 1.87B 11.84B 4.71B 57.89B 4.97B 4.86B 203B |
| Net income | 175M 1.36B 147M 134M 128M 238M 15.85B 247M 1.56B 621M 7.63B 655M 641M 26.8B | 211M 1.65B 178M 162M 155M 287M 19.13B 298M 1.88B 749M 9.21B 790M 774M 32.34B |
| Net Debt | -93.06M -727M -78.51M -71.62M -68.27M -127M -8.45B -132M -832M -331M -4.07B -349M -342M -14.28B | -26.62M -208M -22.45M -20.48M -19.53M -36.28M -2.42B -37.64M -238M -94.6M -1.16B -99.82M -97.77M -4.09B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-02-15 | 12.60 $ | -2.25% | 176,000 |
| 26-02-13 | 12.89 $ | +4.97% | 7,484,044 |
| 26-02-12 | 12.28 $ | -3.08% | 4,643,168 |
| 26-02-11 | 12.67 $ | +2.18% | 4,326,622 |
| 26-02-10 | 12.40 $ | +0.90% | 7,531,409 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Equities
- 2096 Stock
Select your edition
All financial news and data tailored to specific country editions
